← Database
Neuropeptide

Vasoactive Intestinal Peptide (VIP)

Third-party suppliers · research use only · not an endorsement. Some links are affiliate links — purchases made through them may earn this site a commission.
Overview

A naturally occurring 28-amino-acid neuropeptide with well-characterized physiology (vasodilation, secretion, immune modulation); as a therapeutic it is largely experimental, with limited approved use and short biological half-life.

How it works

Vasoactive intestinal peptide (VIP) is a natural signaling molecule found throughout the body, including the nervous system, gut, lungs, and immune tissue. As its name suggests, it was first noted for relaxing blood vessels and influencing intestinal secretion, but it is now understood as a broad regulator that affects circulation, glandular secretion, smooth-muscle tone, and immune activity. It belongs to the same family as the hormone secretin.

VIP works by binding to specific cell-surface receptors that raise intracellular signaling molecules, producing effects such as widening of blood vessels, relaxation of airway and gut muscle, and a generally anti-inflammatory, immune-calming influence. Because of this profile, it has been investigated in conditions ranging from pulmonary hypertension and airway disease to inflammatory and autoimmune disorders, and it has attracted interest in some wellness communities.

In practice, VIP is mostly a research and experimental agent rather than a mainstream approved drug, and a major obstacle is that the natural peptide is broken down very quickly in the body. Claims about specific health benefits, particularly outside controlled studies, often exceed the rigorous human evidence. Safety, optimal use, and real-world effectiveness for most proposed indications are not well established.

Mechanism · Detailed Analysis
Molecular targetVIP is a 28-amino-acid peptide that signals primarily through the class-B G-protein-coupled receptors VPAC1 and VPAC2 (and is related to the PAC1/PACAP system). These receptors are widely distributed across vascular, gastrointestinal, pulmonary, neural, and immune tissues.
Signaling & downstream effectsReceptor activation predominantly raises intracellular cyclic AMP via Gs, leading to smooth-muscle relaxation (vasodilation, bronchodilation), stimulation of secretion, and modulation of immune cells toward a generally anti-inflammatory phenotype. Effects are highly tissue-dependent.
PharmacokineticsAs a native peptide, VIP has a very short circulating half-life due to rapid enzymatic degradation, which limits practical therapeutic use and has motivated analog and delivery-route research. It is not reliably orally active.
CaveatsWhile VIP's physiology is well characterized, its use as a therapeutic is largely experimental and not broadly approved. Many specific health claims outrun rigorous human data, and safety in non-studied uses is not established.
Published EvidenceLoading cited studies from PubMed…
Human Data ···

Searching the published record…

Animal ···

Searching the published record…

In Vitro ···

Searching the published record…

Educational aggregation of public literature. Not medical advice and not a recommendation to use any compound. Many compounds here are not approved for human use. Consult a licensed clinician.